Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes

In VivoSelection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model

(2015) S. Hendrickx et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Experimental Resistance to Drug Combinations in Leishmania donovani: Metabolic and Phenotypic Adaptations

(2015) Maya Berg et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Intracellular amastigote replication may not be required for successful in vitro selection of miltefosine resistance in Leishmania infantum

(2015) S. Hendrickx et al.   PARASITOLOGY RESEARCH

Multi-analytical platform metabolomic approach to study miltefosine mechanism of action and resistance in Leishmania

(2014) Gisele A. B. Canuto et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Functional role of evolutionarily highly conserved residues, N-glycosylation level and domains of theLeishmaniamiltefosine transporter-Cdc50 subunit

(2014) Sebastián García-Sánchez et al.   BIOCHEMICAL JOURNAL

An update on pharmacotherapy for leishmaniasis

(2014) Shyam Sundar et al.   EXPERT OPINION ON PHARMACOTHERAPY

Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?

(2014) Manu Vanaerschot et al.   Expert Review of Anti-Infective Therapy

Failure of Miltefosine in Visceral Leishmaniasis Is Associated With Low Drug Exposure

(2014) T. P. C. Dorlo et al.   JOURNAL OF INFECTIOUS DISEASES

Proteomic analysis of the soluble proteomes of miltefosine-sensitive and -resistant Leishmania infantum chagasi isolates obtained from Brazilian patients with different treatment outcomes

(2014) Juliana B.T. Carnielli et al.   Journal of Proteomics

Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum

(2014) S. Hendrickx et al.   PARASITOLOGY RESEARCH

Comparative transcript expression analysis of miltefosine-sensitive and miltefosine-resistant Leishmania donovani

(2014) Arpita Kulshrestha et al.   PARASITOLOGY RESEARCH

In vitro Susceptibility of Leishmania donovani to Miltefosine in Indian Visceral Leishmaniasis

(2013) Vijay Kumar Prajapati et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance

(2013) Suman Rijal et al.   CLINICAL INFECTIOUS DISEASES

Miltefosine-unresponsiveLeishmania donovanihas a greater ability than miltefosine-responsiveL. donovanito resist reactive oxygen species

(2013) Mousumi Das et al.   FEBS Journal

(Post-) Genomic approaches to tackle drug resistance in Leishmania

(2013) MAYA BERG et al.   PARASITOLOGY

Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis in India After a Decade of Use

(2012) S. Sundar et al.   CLINICAL INFECTIOUS DISEASES

Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis

(2012) T. P. C. Dorlo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fast gapped-read alignment with Bowtie 2

(2012) Ben Langmead et al.   NATURE METHODS

Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern

(2012) Jyotsna Mishra et al.   PARASITOLOGY RESEARCH

Experimental Induction of Paromomycin Resistance in Antimony-Resistant Strains of L. donovani: Outcome Dependent on In Vitro Selection Protocol

(2012) Sarah Hendrickx et al.   PLoS Neglected Tropical Diseases

Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis

(2012) Vasundhra Bhandari et al.   PLoS Neglected Tropical Diseases

Visceral leishmaniasis: elimination with existing interventions

(2011) Greg Matlashewski et al.   LANCET INFECTIOUS DISEASES

Integrative genomics viewer

(2011) James T Robinson et al.   NATURE BIOTECHNOLOGY

Low Plasma Membrane Expression of the Miltefosine Transport Complex Renders Leishmania braziliensis Refractory to the Drug

(2009) M. P. Sanchez-Canete et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Susceptibilities of Leishmania donovani Promastigote and Amastigote Stages to Antileishmanial Reference Drugs: Practical Relevance of Stage-Specific Differences

(2009) M. Vermeersch et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Sensitivity Testing of Leishmania Clinical Field Isolates: Preconditioning of Promastigotes Enhances Infectivity for Macrophage Host Cells

(2009) R. Inocencio da Luz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

TriTrypDB: a functional genomic resource for the Trypanosomatidae

(2009) Martin Aslett et al.   NUCLEIC ACIDS RESEARCH

Characterization of an ABCG-Like Transporter from the Protozoan Parasite Leishmania with a Role in Drug Resistance and Transbilayer Lipid Movement

(2008) E. Castanys-Munoz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Synthesis of BODIPY-labeled alkylphosphocholines with leishmanicidal activity, as fluorescent analogues of miltefosine

(2008) Valentín Hornillos et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Concordant HIV Infection and Visceral Leishmaniasis in Ethiopia: The Influence of Antiretroviral Treatment and Other Factors on Outcome

(2008) Rachel ter Horst et al.   CLINICAL INFECTIOUS DISEASES

Parasite Susceptibility to Amphotericin B in Failures of Treatment for Visceral Leishmaniasis in Patients Coinfected with HIV Type 1 andLeishmania infantum

(2008) Laurence Lachaud et al.   CLINICAL INFECTIOUS DISEASES

Long-Term Monitoring of Visceral Leishmaniasis in Patients With AIDS

(2008) Nathalie Bourgeois et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients

(2007) Jesús Troya et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES